FAM210B

Across TCGA pan-cancer cohorts, FAM210B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM210B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM210B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM210B expression acts as an unfavorable survival marker, although some lineages such as LUAD and COAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where FAM210B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.697	0.921	.003	24	view →
LUAD	OS	Quartile	All	0.939	0.534	.004	16	view →
PDAC	DFS	Median	II,III,IV	0.317	0.470	.016	7	view →
COAD	DFS	Median	II,III,IV	1.000	0.935	.048	6	view →
HNSC	DFS	Quartile	III,IV	0.736	0.438	.013	6	view →
LSCC	DFS	Median	All	0.552	1.000	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM210B–CCRCC (DFS)

Open the CCRCC breakdown →